Shares of Coherus BioSciences, Inc. (NASDAQ:CHRS – Get Free Report) have received an average recommendation of “Moderate Buy” from the six research firms that are presently covering the company, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $6.92.
A number of equities analysts recently commented on the company. HC Wainwright reaffirmed a “buy” rating and issued a $12.00 target price on shares of Coherus BioSciences in a report on Monday, August 5th. Robert W. Baird decreased their target price on Coherus BioSciences from $9.00 to $8.00 and set an “outperform” rating on the stock in a report on Monday, July 1st. StockNews.com cut Coherus BioSciences from a “buy” rating to a “hold” rating in a report on Friday, September 6th. Finally, UBS Group cut Coherus BioSciences from a “buy” rating to a “neutral” rating and decreased their target price for the stock from $4.00 to $1.50 in a report on Friday, August 16th.
Check Out Our Latest Analysis on CHRS
Hedge Funds Weigh In On Coherus BioSciences
Coherus BioSciences Price Performance
NASDAQ CHRS opened at $1.29 on Friday. The business’s fifty day moving average price is $1.44 and its 200-day moving average price is $1.85. The stock has a market capitalization of $148.00 million, a price-to-earnings ratio of -1.65 and a beta of 0.66. Coherus BioSciences has a 1-year low of $1.20 and a 1-year high of $5.02.
Coherus BioSciences (NASDAQ:CHRS – Get Free Report) last released its quarterly earnings results on Thursday, August 8th. The biotechnology company reported ($0.20) earnings per share for the quarter, beating the consensus estimate of ($0.30) by $0.10. The firm had revenue of $64.98 million for the quarter, compared to the consensus estimate of $57.08 million. Equities research analysts anticipate that Coherus BioSciences will post -1.07 EPS for the current year.
Coherus BioSciences Company Profile
Coherus BioSciences, Inc, a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27.
Recommended Stories
- Five stocks we like better than Coherus BioSciences
- Insider Trades May Not Tell You What You Think
- 3 Leveraged ETFs to Multiply Returns
- What Are Dividend Contenders? Investing in Dividend Contenders
- A Tale of Two Titans: Unveiling the Value in Baidu and JD.com
- Overbought Stocks Explained: Should You Trade Them?
- Is the AI-Capable iPhone 16 the Start of a Sales Super-Cycle?
Receive News & Ratings for Coherus BioSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coherus BioSciences and related companies with MarketBeat.com's FREE daily email newsletter.